Design, Synthesis and Discovery of Picomolar Selective α4β2 Nicotinic Acetylcholine Receptor Ligands

Developing novel and selective compounds that desensitize α4β2 nicotinic acetylcholine receptors (nAChRs) could provide new effective treatments for nicotine addiction, as well as other disorders. Here we report a new class of nAChR ligands that display high selectivity and picomolar binding affinity for α4β2 nicotinic receptors. The novel compounds have <i>K</i>_i values in the range of 0.031–0.26 nM and properties that should make them good candidates as drugs acting in the CNS. The selected lead compound <b>1</b> (VMY-2-95) binds with high affinity and potently desensitizes α4β2 nAChRs. At a dose of 3 mg/kg, compound <b>1</b> significantly reduced rat nicotine self-administration. The overall results support further characterizations of compound <b>1</b> and its analogues in preclinical models of nicotine addiction and perhaps other disorders involving nAChRs